Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.41 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | CASP7 | P55210 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.38 |
| ▸ | HTR3B | O95264 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12893949 | 0.88 | TP53 (0.59) | TP53CYP11B2PDE4BPDE4DPOLB | |
| SCHEMBL13319478 | 0.83 | TP53 (0.52) | TP53CYP11B2PDE4BPDE4DCYP1A2 | |
| SCHEMBL16135780 | 0.83 | TP53 (0.54) | TP53CYP11B2PDE4BPDE4DPOLB | |
| SCHEMBL16136080 | 0.83 | TP53 (0.54) | TP53PDE4BPDE4DCYP1A2CYP3A4 | |
| SCHEMBL2790752 | 0.82 | TP53 (0.65) | TP53PDE4BPDE4DPOLBHTR3E | |
| SCHEMBL16136081 | 0.82 | CYP11B2 (0.44) | TP53CYP11B2NSD3ALDH1A1CYP1A2 | |
| SCHEMBL6161817 | 0.81 | CYP11B2 (0.60) | CYP11B2ALDH1A1HPGD | |
| SCHEMBL16291276 | 0.80 | PDE4B (0.46) | CYP11B2PDE4BPDE4DCYP2C9POLB | |
| Hydrochloric Acid SCHEMBL4923120 | 0.80 | CYP11B2 (0.59) | CYP11B2 | |
| SCHEMBL9539176 | 0.80 | TP53 (0.62) | TP53PDE4BPDE4DALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9944603-B2 | Compounds and methods for the treatment of cystic fibrosis | FLATLEY DISCOVERY LAB, LLC (US) | 2018-04-17 | — | — | US | disclosed |
| US-9944603-B2 | Compounds and methods for the treatment of cystic fibrosis | FLATLEY DISCOVERY LAB, LLC (US) | 2018-04-17 | — | — | US | disclosed |
| US-9944603-B2 | Compounds and methods for the treatment of cystic fibrosis | FLATLEY DISCOVERY LAB, LLC (US) | 2018-04-17 | — | — | US | disclosed |
| US-20170313659-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB LLC (US) | 2017-11-02 | — | — | US | disclosed |
| US-20170313659-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB LLC (US) | 2017-11-02 | — | — | US | disclosed |
| US-20170313659-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB LLC (US) | 2017-11-02 | — | — | US | disclosed |
| US-9771327-B2 | Compounds and methods for the treatment of cystic fibrosis | FLATLEY DISCOVERY LAB, LLC (US) | 2017-09-26 | — | — | US | disclosed |
| US-9771327-B2 | Compounds and methods for the treatment of cystic fibrosis | FLATLEY DISCOVERY LAB, LLC (US) | 2017-09-26 | — | — | US | disclosed |
| US-9771327-B2 | Compounds and methods for the treatment of cystic fibrosis | FLATLEY DISCOVERY LAB, LLC (US) | 2017-09-26 | — | — | US | disclosed |
| US-20140371263-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB (US) | 2014-12-18 | — | — | US | disclosed |
| US-20140371238-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB (US) | 2014-12-18 | — | — | US | disclosed |
| US-20140371238-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB (US) | 2014-12-18 | — | — | US | disclosed |
| US-20140371238-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB (US) | 2014-12-18 | — | — | US | disclosed |
| US-20140371263-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB (US) | 2014-12-18 | — | — | US | disclosed |
| US-20140371263-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB (US) | 2014-12-18 | — | — | US | disclosed |
| WO-2014160478-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB (US) | 2014-10-02 | — | — | WO | disclosed |
| EP-0828754-B1 | DIPEPTIDES WHICH PROMOTE RELEASE OF GROWTH HORMONE | PFIZER (US) | 2005-02-02 | — | — | EP | disclosed |
| US-5936089-A | PIPERIDINE DERIVATIVES; BONE DISORDERS; OBESITY; AGING; CACHEXIA ASSOCIATED WITH AIDS AND CANCER | PFIZER INC (US) | 1999-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170313659-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, SERPINB1, ELANE | TP53 4275/4885CYP11B2 502/4885PDE4B 605/4885 |
| US-20140371238-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, SERPINB1, ELANE | TP53 4275/4885CYP11B2 502/4885PDE4B 605/4885 |
| US-20140371263-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, SLC26A4, ABCB11 | TP53 4522/4885CYP11B2 1082/4885PDE4B 354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.